These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1526 related items for PubMed ID: 33706551

  • 1. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis.
    Rohde LE, Claggett BL, Wolsk E, Packer M, Zile M, Swedberg K, Rouleau J, Pfeffer MA, Desai AS, Lund LH, Kober L, Anand I, Merkely B, Senni M, Shi V, Rizkala A, Lefkowitz M, McMurray JJV, Solomon SD.
    Circ Heart Fail; 2021 Mar; 14(3):e008052. PubMed ID: 33706551
    [Abstract] [Full Text] [Related]

  • 2. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD, Claggett B, Desai AS, Packer M, Zile M, Swedberg K, Rouleau JL, Shi VC, Starling RC, Kozan Ö, Dukat A, Lefkowitz MP, McMurray JJ.
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study.
    Jain AR, Aggarwal RK, Rao NS, Billa G, Kumar S.
    Indian Heart J; 2020 Mar; 72(6):535-540. PubMed ID: 33357641
    [Abstract] [Full Text] [Related]

  • 4. Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study: Effect Modification by Left Ventricular Ejection Fraction and Sex.
    Mitchell GF, Solomon SD, Shah AM, Claggett BL, Fang JC, Izzo J, Abbas CA, Desai AS, EVALUATE-HF Investigators*.
    Circ Heart Fail; 2021 Mar; 14(3):e007891. PubMed ID: 33663237
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF.
    Ehteshami-Afshar S, Mooney L, Dewan P, Desai AS, Lang NN, Lefkowitz MP, Petrie MC, Rizkala AR, Rouleau JL, Solomon SD, Swedberg K, Shi VC, Zile MR, Packer M, McMurray JJV, Jhund PS, Hawkins NM.
    J Am Heart Assoc; 2021 Feb 16; 10(4):e019238. PubMed ID: 33522249
    [Abstract] [Full Text] [Related]

  • 7. Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF.
    Selvaraj S, Claggett BL, Pfeffer MA, Desai AS, Mc Causland FR, McGrath MM, Anand IS, van Veldhuisen DJ, Kober L, Janssens S, Cleland JGF, Pieske B, Rouleau JL, Zile MR, Shi VC, Lefkowitz MP, McMurray JJV, Solomon SD.
    Eur J Heart Fail; 2020 Nov 16; 22(11):2093-2101. PubMed ID: 32840930
    [Abstract] [Full Text] [Related]

  • 8. Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/Valsartan.
    Curtain JP, Adamson C, Docherty KF, Jhund PS, Desai AS, Lefkowitz MP, Rizkala AR, Rouleau JL, Swedberg K, Zile MR, Solomon SD, Packer M, McMurray JJV.
    JACC Heart Fail; 2023 Jul 16; 11(7):749-759. PubMed ID: 37407154
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
    Jering KS, Zannad F, Claggett B, Mc Causland FR, Ferreira JP, Desai A, Barkoudah E, McMurray JJV, Pfeffer MA, Solomon SD.
    JACC Heart Fail; 2021 Jan 16; 9(1):13-24. PubMed ID: 33189633
    [Abstract] [Full Text] [Related]

  • 12. Insights into implementation of sacubitril/valsartan into clinical practice.
    Martens P, Beliën H, Dupont M, Mullens W.
    ESC Heart Fail; 2018 Jun 16; 5(3):275-283. PubMed ID: 29464879
    [Abstract] [Full Text] [Related]

  • 13. Mode of Death in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF Trial.
    Desai AS, Vaduganathan M, Cleland JG, Claggett BL, Barkoudah E, Finn P, McCausland FR, Yilmaz MB, Lefkowitz M, Shi V, Pfeffer MA, McMurray JJV, Solomon SD.
    Circ Heart Fail; 2021 Dec 16; 14(12):e008597. PubMed ID: 34807713
    [Abstract] [Full Text] [Related]

  • 14. Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.
    McMurray JJV, Jackson AM, Lam CSP, Redfield MM, Anand IS, Ge J, Lefkowitz MP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Rizkala AR, Sabarwal SV, Shah AM, Shah SJ, Shi VC, van Veldhuisen DJ, Zannad F, Zile MR, Cikes M, Goncalvesova E, Katova T, Kosztin A, Lelonek M, Sweitzer N, Vardeny O, Claggett B, Jhund PS, Solomon SD.
    Circulation; 2020 Feb 04; 141(5):338-351. PubMed ID: 31736337
    [Abstract] [Full Text] [Related]

  • 15. Analysis of the PARAGON-HF Study Results Using Win Ratio.
    Yoon M, Kim W, Kook W, Park JJ, Greenberg B.
    Circ Heart Fail; 2024 Sep 04; 17(9):e011860. PubMed ID: 39193709
    [Abstract] [Full Text] [Related]

  • 16. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK, Claggett BL, Solomon SD, McMurray JJV, Packer M, Zile MR, Desai AS, Rouleau JL, Swedberg K, Fonarow GC.
    JAMA Cardiol; 2018 Dec 01; 3(12):1226-1231. PubMed ID: 30484837
    [Abstract] [Full Text] [Related]

  • 17. Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction.
    Tan NY, Sangaralingham LR, Sangaralingham SJ, Yao X, Shah ND, Dunlay SM.
    JACC Heart Fail; 2020 Jan 01; 8(1):43-54. PubMed ID: 31838035
    [Abstract] [Full Text] [Related]

  • 18. Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF.
    Selvaraj S, Claggett B, Pozzi A, McMurray JJV, Jhund PS, Packer M, Desai AS, Lewis EF, Vaduganathan M, Lefkowitz MP, Rouleau JL, Shi VC, Zile MR, Swedberg K, Solomon SD.
    Circulation; 2019 Oct 22; 140(17):1369-1379. PubMed ID: 31510768
    [Abstract] [Full Text] [Related]

  • 19. Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF.
    Balmforth C, Simpson J, Shen L, Jhund PS, Lefkowitz M, Rizkala AR, Rouleau JL, Shi V, Solomon SD, Swedberg K, Zile MR, Packer M, McMurray JJV.
    JACC Heart Fail; 2019 Jun 22; 7(6):457-465. PubMed ID: 31078482
    [Abstract] [Full Text] [Related]

  • 20. Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure).
    Vardeny O, Claggett B, Kachadourian J, Pearson SM, Desai AS, Packer M, Rouleau J, Zile MR, Swedberg K, Lefkowitz M, Shi V, McMurray JJV, Solomon SD.
    Circ Heart Fail; 2018 Apr 22; 11(4):e004745. PubMed ID: 29643067
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 77.